Medical management of frontotemporal dementia

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


There are no Food and Drug Administration (FDA)-approved medications for the medical management of frontotemporal dementia and its related disorders, so all management recommendations are necessarily off-label and borrowed from experience with Alzheimer's disease, psychiatric disease, and related medical illnesses. Six areas of pharmacotherapeutic consideration are prevention (primary and secondary), intellectual decline, behavioral disorders (such as depression, anxiety, and psychosis), sleep disorders, frequently associated disorders (including motor neuron disease), and abrupt decline. In addition to pharmacotherapy, important lifestyle issues confronting the clinician include driving cessation, securing any weapons maintained at home, assisted living, and caregiver burnout.

Original languageEnglish (US)
Pages (from-to)489-498
Number of pages10
JournalAmerican Journal of Alzheimer's Disease and Other Dementias
Issue number6
StatePublished - Jan 2008


  • Dementia and motor neuron disease
  • Frontotemporal dementia
  • Pharmacotherapy of dementia

ASJC Scopus subject areas

  • General Neuroscience
  • Clinical Psychology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health


Dive into the research topics of 'Medical management of frontotemporal dementia'. Together they form a unique fingerprint.

Cite this